DelveInsight’s “Glioma Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the glioma, historical and forecasted epidemiology as well as the glioma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Discover Key Insights into the Glioma Market with DelveInsight’s In-Depth Report @ Glioma Market Size

 

Key Takeaways from the Glioma Market Report

• In November 2024:- Nuvation Bio Inc.- This is a Phase 2, multicenter, open label, two parts, clinical study to evaluate the efficacy, safety, and PK of safusidenib. Patients with recurrent or progressive histologically confirmed IDH1 mutant WHO Grade 2/3 glioma10 outside Japan, will be enrolled in this study. It was divided into 2 parts.
• In November 2024:- Eli Lilly and Company- A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
• The United States contributed to the largest incident population of glioma, acquiring ~40% of the 7MM in 2023.
• Among EU4 and the UK, Germany accounted for the highest number of glioma cases, followed by France, whereas Spain had the lowest number of cases in 2023.
• According to DelveInsight estimates, in the US, among all the grades, Grade IV accounted for the highest number of incident cases (~68%), followed by Grade II glioma (~13%), while Grade I had the least number of cases (~6%).
• The major types of glioma include diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytic tumors, pilocytic astrocytoma, and others. In 2023, glioblastoma contributed to the highest number of glioma cases i.e., around 67% of the total population.
• In the US, among all the age groups, 60–74 years accounted for the highest number of glioma cases, i.e., around 36%, in 2023, followed by the age-group 45–59 years (25%).
• The leading Glioma Companies such as Memorial Sloan Kettering Cancer Center, AnHeart Therapeutics Inc., Eli Lilly and Company, Chimerix, Plus Therapeutics, Chimerix, Istari Oncology, Inc., Armando Santoro, MD, Epitopoietic Research Corporation, Aveta Biomics, Inc., Chimerix, Day One Biopharmaceuticals, Incyte Corporation, Nerviano Medical Sciences, Daiichi Sankyo Co., Ltd., Everfront Biotech Co., Ltd., Ashish Shah, Oblato, Inc., Day One Biopharmaceuticals, BioMimetix JV, LLC, and others
• Promising Glioma Therapies such as Pembrolizumab, Safusidenib, Abemaciclib, ONC201, Rhenium Liposome Treatment, ONC201, PVSRIPO, Temodal, ERC1671, APG-157, ONC201, Tovorafenib, Pemigatinib, NMS-03305293, DS-1001b, Cerebraca wafer, DB107-RRV, OKN-007, DAY101, BMX-001, and others

 

Stay ahead in the Glioma Therapeutics Market with DelveInsight’s Strategic Report @ Glioma Market Outlook

 

Glioma Epidemiology Segmentation in the 7MM

• total incident cases of glioma
• grade-specific cases of glioma
• age-specific cases of glioma
• type-specific cases of glioma

 

Download the report to understand which factors are driving Glioma epidemiology trends @ Glioma Prevalence

 

Glioma Marketed Therapies

 

• AVASTIN: Genentech

AVASTIN (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as an angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. In December 2017, the US FDA approved bevacizumab (AVASTIN) for treating adults with recurrent GBM that has progressed following prior therapy.

Owing to AVASTIN’s (bevacizumab) patent term expiration, the US FDA has approved three biosimilars: MVASI (Amgen), ZIRABEV (Pfizer), and ALYMSYS (Amneal Pharma). In 2017, the US FDA approved the first AVASTIN biosimilar, Amgen’s MVASI.

 

• TEMODAR (temozolomide): Merck

The active pharmaceutical ingredient in TEMODAR/TEMODAL is an imidazotetrazine derivative of the alkylating agent dacarbazine. Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for GBM. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. In July 2006, the Japan Ministry of Health, Labor and Welfare (MHLW) approved TEMODAL (temozolomide) Capsules for the treatment of malignant glioma. Generic versions of the drug are also available due to patent expiration.

 

Emerging Glioma Drugs

• Ofranergene obadenovec (VB-111): VBL Therapeutics

Ofranergene obadenovec (VB-111) is a first-in-class, targeted anticancer gene-therapy agent that VBL Therapeutics is developing to treat a wide range of solid tumors such as GBM. It is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. The drug has been rewarded Orphan Drug Designation from both US FDA and EMA for the treatment of patients with GBM. In addition, it has also been granted Fast Track Designation by the US FDA for prolongation of survival in patients with rGBM.

 

• SurVaxM: MimiVax

SurVaxM by MimiVax is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein in 95% of GBM and other cancers. The vaccine has dual mechanisms of action to stimulate a patient’s T-cell immunity and employs antibody-directed inhibition of the survivin pathway to control tumor growth and prevent or delay tumor recurrence. The Phase IIa study showed that the overall survival was 25.9 months in MGMT methylated patients at 41.4 months, and in MGMT unmethylated patients was 16.5 months. Similarly, the FSecorded was 17.9 months MGMT methylated patients higher than in MGMT unmethylated patients. Apart from SurVaxM other players developing vaccines are Aivita Biomedical, Immunomic Therapeutics, Northwest Therapeutics and TVAX Biomedical.

 

• Vorasidenib (AG-881): Servier

Vorasidenib (AG-881), a first-in-class, dual inhibitor of mIDH1/2, was specifically developed for improved penetration across the blood–brain barrier and showed brain penetrance and reduced tumor growth in an orthotopic model of mIDH glioma. Phase I interim data suggested that tumor-intrinsic and -extrinsic mechanisms underlie 2-HG suppression by vorasidenib and ivosidenib. Vorasidenib demonstrated a favorable safety profile and is currently being evaluated in the registration-enabling Phase III INDIGO study as a potential treatment for patients with residual or recurrent Grade II low-grade glioma.

 

• Tovorafenib (DAY101): Day One Biopharmaceuticals

Tovorafenib (DAY101) is an investigational, oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which may offer an important alternative for people with primary brain tumors or brain metastases of solid tumors. Currently, DAY101 is under evaluation in a pivotal Phase II clinical trial (FIREFLY-1) evaluating its safety and efficacy in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma (pLGG) harboring a known BRAF alteration.

 

Get In-Depth Knowledge on Glioma Market Trends and Forecasts with DelveInsight @ Glioma Treatment Market

 

Glioma Market Outlook

Gliomas can have four different grades of differentiation. Grade I gliomas show the highest level of differentiation and are the least malignant, while Grade IV tumors are the least differentiated and most malignant. A large multidisciplinary team of medical specialists and health professionals is required to treat patients with gliomas. Glioma treatment is quite challenging as some cells may respond well to certain therapies while others may not be affected at all. Because of this, the treatment plan for glioma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery, followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

 

Glioma Therapies and Companies

• Pembrolizumab: Memorial Sloan Kettering Cancer Center
• safusidenib: AnHeart Therapeutics Inc.
• Abemaciclib: Eli Lilly and Company
• ONC201: Chimerix
• Rhenium Liposome Treatment: Plus Therapeutics
• ONC201: Chimerix
• PVSRIPO: Istari Oncology, Inc.
• Temodal: Armando Santoro, MD
• ERC1671: Epitopoietic Research Corporation
• APG-157: Aveta Biomics, Inc.
• ONC201: Chimerix
• Tovorafenib: Day One Biopharmaceuticals
• Pemigatinib: Incyte Corporation
• NMS-03305293: Nerviano Medical Sciences
• DS-1001b: Daiichi Sankyo Co., Ltd.
• Cerebraca wafer: Everfront Biotech Co., Ltd.
• DB107-RRV: Ashish Shah
• OKN-007: Oblato, Inc.
• DAY101: Day One Biopharmaceuticals
• BMX-001: BioMimetix JV, LLC

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Glioma Market Report @ Glioma Market Drivers and Barriers

 

Scope of the Glioma Market Report

• Coverage- 7MM
• Glioma Companies- Memorial Sloan Kettering Cancer Center, AnHeart Therapeutics Inc., Eli Lilly and Company, Chimerix, Plus Therapeutics, Chimerix, Istari Oncology, Inc., Armando Santoro, MD, Epitopoietic Research Corporation, Aveta Biomics, Inc., Chimerix, Day One Biopharmaceuticals, Incyte Corporation, Nerviano Medical Sciences, Daiichi Sankyo Co., Ltd., Everfront Biotech Co., Ltd., Ashish Shah, Oblato, Inc., Day One Biopharmaceuticals, BioMimetix JV, LLC, and others
• Glioma Therapies- Pembrolizumab, Safusidenib, Abemaciclib, ONC201, Rhenium Liposome Treatment, ONC201, PVSRIPO, Temodal, ERC1671, APG-157, ONC201, Tovorafenib, Pemigatinib, NMS-03305293, DS-1001b, Cerebraca wafer, DB107-RRV, OKN-007, DAY101, BMX-001, and others
• Glioma Therapeutic Assessment: Glioma Current marketed and Glioma Emerging Therapies
• Glioma Market Dynamics: Glioma Market drivers and Glioma Market Barriers

 

Table of Contents

1. Glioma Market Report Introduction

2. Executive Summary for Glioma

3. SWOT analysis of Glioma

4. Glioma Patient Share (%) Overview at a Glance

5. Glioma Market Overview at a Glance

6. Glioma Disease Background and Overview

7. Glioma Epidemiology and Patient Population

8. Country-Specific Patient Population of Glioma

9. Glioma Current Treatment and Medical Practices

10. Glioma Unmet Needs

11. Glioma Emerging Therapies

12. Glioma Market Outlook

13. Country-Wise Glioma Market Analysis (2020–2034)

14. Glioma Market Access and Reimbursement of Therapies

15. Glioma Market Drivers

16. Glioma Market Barriers

17. Glioma Appendix

18. Glioma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity